Skip to Main Content
Corporate

Double Marker Test

General Information About the Test

The Double Marker Test, performed between the 11th and 14th weeks of pregnancy, is the first and most important step in the pregnancy screening process to evaluate the risks of chromosomal anomalies such as Down Syndrome (Trisomy 21) and Edwards Syndrome (Trisomy 18) in the baby in the womb. It involves both a detailed ultrasonographic examination (nuchal translucency measurement) and a blood test taken from the mother.

Test Process and Preparation

Steps of the double marker test and pregnancy evaluations.

In the first stage, a perinatologist or obstetrician measures the fluid accumulation at the back of the baby's neck (NT - Nuchal Translucency) and the presence of the nasal bone via ultrasound. In the second stage, blood is drawn from the mother to check the PAPP-A and Free Beta-HCG hormone levels. All this data is converted into a risk ratio by a computer.

The double marker test is not a diagnostic (definitive diagnosis) test; it determines whether the risk group is "high" or "low". If the risk is high, it does not mean the baby is definitively affected; advanced tests such as Fetal DNA testing or CVS/Amniocentesis are recommended to clarify the situation.

Because the blood sample taken from the expectant mother does not contain hormones affected by food, whether you are fasting or full does not matter for the double marker test.

The information on this page is for informational purposes only. The results of medical tests must be evaluated by specialist physicians.

You can find all the information regarding your treatment and hospital stay process in this section.

Patient Visits

Details

Patient Admission

Details

Your Hospital Stay

Details

Surgeries

Details
E-Appointment
E-Consultation
Contact Us
App

Çakırtepe Hospital

Mobil Uygulama ★★★★★